These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23789809)

  • 1. Effect of fluoroquinolone resistance selection on the fitness of three strains of Clostridium perfringens.
    Park M; Sutherland JB; Kim JN; Rafii F
    Microb Drug Resist; 2013 Dec; 19(6):421-7. PubMed ID: 23789809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens.
    Park S; Park M; Rafii F
    BMC Microbiol; 2013 Mar; 13():50. PubMed ID: 23452396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitutions of amino acids in alpha-helix-4 of gyrase A confer fluoroquinolone resistance on Clostridium perfringens.
    Rafii F; Park M
    Arch Microbiol; 2007 Feb; 187(2):137-44. PubMed ID: 17051403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens.
    Rafii F; Park M; Bryant AE; Johnson SJ; Wagner RD
    Antimicrob Agents Chemother; 2008 Mar; 52(3):895-900. PubMed ID: 18160514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the metabolic activities of four wild-type Clostridium perfringens strains with their gatifloxacin-selected resistant mutants.
    Rafii F; Park M; Gamboa da Costa G; Camacho L
    Arch Microbiol; 2009 Dec; 191(12):895-902. PubMed ID: 19855959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of an ATP-binding cassette from Clostridium perfringens with homology to an ABC transporter from Clostridium hathewayi.
    Rafii F; Park M; Carman RJ
    Anaerobe; 2009 Aug; 15(4):116-21. PubMed ID: 19655423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure.
    Yan M; Sahin O; Lin J; Zhang Q
    J Antimicrob Chemother; 2006 Dec; 58(6):1154-9. PubMed ID: 17023497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi.
    Rafii F; Park M; Wynne R
    Chemotherapy; 2005 Aug; 51(5):256-62. PubMed ID: 16088123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains.
    Park M; Rafii F
    Int J Microbiol; 2014; 2014():456979. PubMed ID: 25587280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
    Balsalobre L; de la Campa AG
    Antimicrob Agents Chemother; 2008 Mar; 52(3):822-30. PubMed ID: 18160515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
    Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
    Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.